# Cigna Group: overview

CI · NYSE · CIK 1739940 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ci.md) · [Financials](/companies/ci/financials.md) · [Filings](/companies/ci/filings.md) · [Insiders](/companies/ci/insiders.md)

Latest reported revenue: [$71.67bn](/filings/0001739940-26-000065.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:Revenues, accession 0001739940-26-000065).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [63.7](/filings/0001739940-25-000037.md) | [65.6 d](/filings/0001739940-26-000006.md) | [65.5](/filings/0001739940-26-000043.md) | [67.2](/filings/0001739940-26-000065.md) | [69.7](/filings/0001739940-25-000037.md) | [72.5 d](/filings/0001739940-26-000006.md) | [68.5](/filings/0001739940-26-000043.md) | [71.7](/filings/0001739940-26-000065.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [4.0%](/filings/0001739940-25-000037.md) | [3.3% d](/filings/0001739940-26-000006.md) | [3.0%](/filings/0001739940-26-000043.md) | [3.4%](/filings/0001739940-26-000065.md) | [3.7%](/filings/0001739940-25-000037.md) | [3.2% d](/filings/0001739940-26-000006.md) | [3.4%](/filings/0001739940-26-000043.md) | [3.7%](/filings/0001739940-26-000065.md) |
| Net margin | % | [1.3%](/filings/0001739940-25-000037.md) | [1.8% d](/filings/0001739940-26-000006.md) | [2.0%](/filings/0001739940-26-000043.md) | [2.3%](/filings/0001739940-26-000065.md) | [2.8%](/filings/0001739940-25-000037.md) | [1.3% d](/filings/0001739940-26-000006.md) | [2.4%](/filings/0001739940-26-000043.md) | [2.3%](/filings/0001739940-26-000065.md) |
| Diluted EPS | $ per share | [2.63](/filings/0001739940-25-000037.md) | not reported | [4.85](/filings/0001739940-26-000043.md) | [5.71](/filings/0001739940-26-000065.md) | [6.98](/filings/0001739940-25-000037.md) | not reported | [6.26](/filings/0001739940-26-000043.md) | [6.29](/filings/0001739940-26-000065.md) |
| Free cash flow | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [174](/filings/0001739940-24-000005.md) | [181](/filings/0001739940-25-000009.md) | [195](/filings/0001739940-26-000006.md) | [247](/filings/0001739940-26-000006.md) | [275](/filings/0001739940-26-000006.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [4.6%](/filings/0001739940-24-000005.md) | [4.7%](/filings/0001739940-25-000009.md) | [4.4%](/filings/0001739940-26-000006.md) | [3.8%](/filings/0001739940-26-000006.md) | [3.3%](/filings/0001739940-26-000006.md) |
| Net margin | % | [3.1%](/filings/0001739940-24-000005.md) | [3.8%](/filings/0001739940-25-000009.md) | [2.6%](/filings/0001739940-26-000006.md) | [1.4%](/filings/0001739940-26-000006.md) | [2.2%](/filings/0001739940-26-000006.md) |
| Diluted EPS | $ per share | [15.75](/filings/0001739940-24-000005.md) | [21.41](/filings/0001739940-25-000009.md) | [17.39](/filings/0001739940-26-000006.md) | [12.12](/filings/0001739940-26-000006.md) | [22.18](/filings/0001739940-26-000006.md) |
| Free cash flow | $bn | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:Revenues; Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ci/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.46bn | 23,438,250 |  | Added +840,098 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $4.76bn | 17,276,296 |  | Added +154,227 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $3.50bn | 12,682,259 |  | Added +399,118 |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $3.36bn | 12,173,875 |  | Added +618,088 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $2.90bn | 10,443,691 |  | Reduced −1,151,491 |
| [Sanders Capital, LLC](/funds/1508097.md) | 2026-06-30 | $2.80bn | 10,144,617 |  | Reduced −145,765 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $2.21bn | 8,018,189 |  | Reduced −2,939,083 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.72bn | 6,268,347 |  | Added +68,005 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.72bn | 6,228,614 |  | Added +65,176 |
| [GQG Partners LLC](/funds/1697233.md) | 2026-06-30 | $1.63bn | 5,908,707 |  | Reduced −93,741 |

## Recent filings

[All 1,019 filings](/companies/ci/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-09 | 20:15 ET | [8-K](/filings/0001140361-26-039271.md) | 5.02 Departure or appointment of officers or directors | 0001140361-26-039271 |
| 2026-09-30 | 11:12 ET | [8-K](/filings/0001140361-26-038056.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-038056 |
| 2026-07-30 | 16:37 ET | [10-Q](/filings/0001739940-26-000065.md) | Quarterly report, period 2026-06-30 | 0001739940-26-000065 |
| 2026-07-30 | 10:16 ET | [8-K](/filings/0001140361-26-030135.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-030135 |
| 2026-05-13 | 10:01 ET | [8-K](/filings/0001140361-26-020906.md) | 7.01 Regulation FD disclosure | 0001140361-26-020906 |
| 2026-04-30 | 15:47 ET | [10-Q](/filings/0001739940-26-000043.md) | Quarterly report, period 2026-03-31 | 0001739940-26-000043 |
| 2026-04-30 | 10:15 ET | [8-K](/filings/0001140361-26-017971.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-017971 |
| 2026-04-27 | 20:26 ET | [8-K](/filings/0001140361-26-017123.md) | 5.07 Shareholder vote results | 0001140361-26-017123 |
| 2026-03-13 | 20:36 ET | [DEF 14A](/filings/0001739940-26-000023.md) | Proxy statement, period 2026-04-22 | 0001739940-26-000023 |
| 2026-03-03 | 12:42 ET | [8-K](/filings/0001140361-26-007450.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-007450 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001739940-26-000006.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9f91adfe-8ccc-4dc7-8aaf-3d8ca787e3aa)

## About the filer

- CIK: 1739940
- Tickers: CI
- Exchange: NYSE
- SIC code: 6324 Hospital & Medical Service Plans
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.